Full Press Release Details
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) --Apollomics Inc.(Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.
“Our new partnership with LaunXP provides an opportunity to expand the clinical dataset for vebreltinib to include combination therapy with an EGFRi. This class is currently the frontline treatment for many patients with NSCLC, and combination therapy with vebreltinib may delay the emergence of resistance to this foundational therapeutic class,” said Dr. Guo-Liang Yu, CEO of Apollomics. “We will continue to seek collaborative opportunities to maximize the global opportunity for vebreltinib, both as a single agent and in combination approaches for the treatment of cancers.”
“In addition, preliminary results we announced in 2024 for various SPARTA cohorts highlight the opportunity for vebreltinib in the treatment of various tumors with c-Met dysregulation. This includes new interim data for the treatment of NSCLC with MET Amplification, new interim data for the treatment of non-CNS solid tumors with MET fusions, and an incremental update for NSCLC with Met Exon 14 skipping,” continued Dr. Yu.
Pipeline Update
Business Highlights
Full Year 2024 Financial Results
AboutApollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives including with respect to the expected payments under its agreement with LaunXP, anticipated outcomes from the development and commercialization of vebreltinib with an EGFR inhibitor and with respect to updates for other programs in the pipeline, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics’ operations and the continued listing of Apollomics’ securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.
Investor Contact:
Eric RibnerLifeSci Advisors, LLC(646) 751-4363eric@lifesciadvisors.com
| APOLLOMICS INC.CONSOLIDATED STATEMENTS OF FINANCIAL POSITION(UNAUDITED)(All amounts in thousands of $) | ||||||||
| As of December 31, | ||||||||
| 2023 | 2024 | |||||||
| $ | $ | |||||||
| Non-current assets | ||||||||
| Plant and equipment, net | $ | 161 | $ | 92 | ||||
| Right-of-use assets | 425 | 927 | ||||||
| Intangible assets, net | 14,757 | 1,737 | ||||||
| Rental deposits | 119 | 75 | ||||||
| Total non-current assets | 15,462 | 2,831 | ||||||
| Current assets | ||||||||
| Deposits, prepayments and deferred expenses | 2,108 | 501 | ||||||
| Financial assets at FVTPL | 5,761 | — | ||||||
| Cash and cash equivalents | 32,056 | 9,766 | ||||||
| Total current assets | 39,925 | 10,267 | ||||||
| Total assets | 55,387 | 13,098 | ||||||
| Current liabilities | ||||||||
| Other payables and accruals | 9,162 | 7,166 | ||||||
| Short term bank loans | 4,236 | — | ||||||
| Lease liabilities, current portion | 158 | 233 | ||||||
| Total current liabilities | 13,556 | 7,399 | ||||||
| Net current assets | 26,369 | 2,868 | ||||||
| Total assets less current liabilities | 41,831 | 5,699 | ||||||
| Non-current liabilities | ||||||||
| Lease liabilities, noncurrent portion | 267 | 733 | ||||||
| Warrant liabilities at FVTPL | 330 | 102 | ||||||
| Total non-current liabilities | 597 | 835 | ||||||
| Net assets | $ | 41,234 | $ | 4,864 | ||||
| Equity | ||||||||
| Share capital | 9 | 11 | ||||||
| Share premium | 661,474 | 666,528 | ||||||
| Reserves | 26,716 | 39,148 | ||||||
| Accumulated losses | (646,965 | ) | (700,823 | ) | ||||
| Total equity | $ | 41,234 | $ | 4,864 |
| APOLLOMICS INC.CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS(UNAUDITED)(All amounts in thousands of $, except for per share data) | ||||||||||||
| Years ended December 31, | ||||||||||||
| 2022 | 2023 | 2024 | ||||||||||
| Other income | $ | 1,447 | $ | 1,217 | $ | 1,489 | ||||||
| Foreign exchange gains (losses) | (829 | ) | 1,191 | 145 | ||||||||
| Fair value change of financial assets at fair value through profit and loss (“FVTPL”) | 323 | 821 | 198 | |||||||||
| Fair value change of financial liabilities at FVTPL | — | 1,597 | 222 | |||||||||
| Fair value change of convertible preferred shares | (189,646 | ) | (76,430 | ) | — | |||||||
| Research and development expenses | (35,457 | ) | (34,193 | ) | (24,566 | ) | ||||||
| Administrative expenses | (9,947 | ) | (20,641 | ) | (17,768 | ) | ||||||
| Impairment of intangible assets | — | — | (13,000 | ) | ||||||||
| Finance costs | (93 | ) | (150 | ) | (179 | ) | ||||||
| Other expense | (6,608 | ) | (46,003 | ) | (140 | ) | ||||||
| Loss before taxation | (240,810 | ) | (172,591 | ) | (53,599 | ) | ||||||
| Income tax expenses | (1 | ) | (10 | ) | (259 | ) | ||||||
| Loss and total comprehensive loss for the period, net of taxation, attributable to owners of the Company | (240,811 | ) | (172,601 | ) | (53,858 | ) | ||||||
| Loss per share – Basic and diluted | $ | (844.95 | ) | $ | (231.99 | ) | $ | (52.80 | ) |